Conscious sedation during subcutaneous implantable cardioverter-defibrillator implantation using the intermuscular technique
- 135 Downloads
The subcutaneous implantable cardioverter-defibrillator (S-ICD) system is an established therapy for the prevention of sudden cardiac death (SCD) and an alternative to a transvenous implantable cardioverter-defibrillator (ICD) system in selected patients. S-ICDs are usually implanted under general anesthesia. The purpose of the present study was to describe the technical feasibility and safety of local anesthesia with conscious sedation as an alternative to general anesthesia during S-ICD implantation using the intermuscular technique.
We conducted a retrospective, single-center study on patients undergoing S-ICD implantation using the intermuscular technique at our center between February 2016 and May 2018. All procedures were performed under controlled sedation with propofol and midazolam. Local anesthesia was used for all procedures.
Twenty-two patients (17 men and 5 women) with a mean age of 51.1 ± 16.2 years were included. The indication for S-ICD implantation was primary prevention in 18 (81.8%) patients. The mean dose of midazolam and propofol administered was 7.8 ± 2.3 mg and 72.7 ± 37.4 mg, respectively. The procedural success rate was 100%, with no apneic or hypoxic episodes or other complications requiring therapeutic intervention. None of the patients required conversion to general anesthesia. All patients were comfortable with the position and appearance of the device.
Our findings suggest that local anesthesia with conscious sedation using propofol and midazolam is a safe and feasible option for S-ICD implantation procedures using an intermuscular technique.
KeywordsS-ICD Intermuscular technique General anesthesia Safety Sedation Sudden cardiac death
American Society of Anesthesiologists
Automated screening tool
Cardiac implantable electronic device
Idiopathic ventricular fibrillation
Richmond Agitation-Sedation Scale
Sudden cardiac death
Subcutaneous implantable cardioverter-defibrillator
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval and consent to participate
The study was approved by the ethics committee of the faculty of medicine of the University of Duisburg-Essen (Reference no. 17-7701-BO), Germany.
- 1.Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC guidelines for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015;17:1601–87.Google Scholar
- 4.Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Multicenter automatic defibrillator implantation trial (MADIT) investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–40.CrossRefGoogle Scholar
- 5.Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Multicenter automatic defibrillator implantation trial II (MADIT II) investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.CrossRefGoogle Scholar
- 13.Essandoh MK, Otey AJ, Abdel-Rasoul M, Stein EJ, Turner KR, Joseph NC, et al. Monitored anesthesia care for subcutaneous cardioverter-defibrillator implantation: a single-center experience. J Cardiothorac Vasc Anesth. 2016;30(5):1228–33. https://doi.org/10.1053/j.jvca.2016.06.007.CrossRefGoogle Scholar
- 14.Essandoh MK, Mark GE, Aasbo JD, Joyner CA, Sharma S, Decena BF, et al. Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. Pacing Clin Electrophysiol. 2018. https://doi.org/10.1111/pace.13364.
- 15.Knops RE, Olde Nordkamp LR, de Groot JR, Wilde AA. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2013;10(8):1240–3. https://doi.org/10.1016/j.hrthm.2013.05.016. Epub 2013 May.
- 16.Winter J, Siekiera M, Shin DI, Meyer C, Kröpil P, Clahsen H, et al. Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications. Europace. 2017;19(12):2036–41. https://doi.org/10.1093/europace/euw297.CrossRefGoogle Scholar
- 20.Miller MA, Bhatt HV, Weiner M, Brouwer TF, Mittnacht AJ, Shariat A, et al. Implantation of the subcutaneous implantable cardioverter-defibrillator with truncal plane blocks. Heart Rhythm. 2018. https://doi.org/10.1016/j.hrthm.2018.02.014.
- 21.Peyrol M, Barraud J, Cautela J, Maille B, Laine M, Bonello L, et al. Controlled sedation with midazolam and analgesis with nalbuphine to alleviate pain in patients undergoing subcutaneous implantable cardioverter defibrillator implantation. J Interv Card Electrophysiol. 2017;49(2):191–6. https://doi.org/10.1007/s10840-017-0255-5.CrossRefGoogle Scholar
- 22.Afzal MR, Mehta D, Evenson C, Pinkhas D, Badin A, Patel D, et al. Perioperative management of oral anticoagulation in patients undergoing implantation of subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2018;15(4):520–3. https://doi.org/10.1016/j.hrthm.2017.11.010.CrossRefGoogle Scholar
- 23.Sessler DI, Sigl JC, Kelley SD, Chamoun NG, Manberg PJ, Saager L, et al. Hospital stay and mortality are increased in patients having a “triple low” of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia. Anesthesiology. 2012;116(6):1195–203. https://doi.org/10.1097/ALN.0b013e31825683dc.CrossRefGoogle Scholar
- 24.Markewitz A. Annual report 2015 of the German cardiac pacemaker and defibrillator register-part 2: implantable cardioverter-defibrillators: cardiac pacemaker working group at the IQTIG - institute for quality assurance and transparency in health care. Herzschrittmacherther Elektrophysiol. 2018;29(1):100–15. https://doi.org/10.1007/s00399-017-0547-6.CrossRefGoogle Scholar